ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

Core Viewpoint - ProPhase Labs has received U.S. Patent No. 12379378-B2 for its biomarker-driven systems and methods aimed at assessing progression risk in Barrett's esophagus and esophageal adenocarcinoma, following the successful validation of its BE-Smart test with over 95% technical success [2][5][6] Group 1: Patent and Technology - The newly issued patent protects the core biomarker methods underlying the BE-Smart test, which is designed for early detection and management of esophageal diseases [2][4] - The patent covers systems and methods for assessing the risk of Barrett's esophagus pathogenesis and esophageal adenocarcinoma progression by detecting key biomarkers such as ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI [4][5] - The BE-Smart test demonstrates compatibility with both brush and forceps biopsies, enhancing early detection and risk stratification in patients with GERD and Barrett's esophagus [3][6] Group 2: Clinical Relevance and Market Position - The issuance of the patent underscores the scientific foundation and clinical relevance of ProPhase Labs' technology, enabling novel treatment approaches and supporting more accurate identification of patients at elevated risk [5][6] - The CEO of ProPhase Labs emphasized that this achievement solidifies the company's leadership in medical innovation and positions them to accelerate commercialization and broaden clinical access to BE-Smart [6] - ProPhase Labs is committed to building a healthier world through innovation, focusing on genomics and diagnostics, including the BE-Smart test for early detection of esophageal cancer [7]